γδ T cells as immune effectors against high-grade gliomas

Immunologic Research

Volumn 45, Issue 1, 2009, Pages 85-95

  Lamb Jr , Lawrence S ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

T cell; Glioblastoma; Glioma; Immunotherapy; Innate immunity; T cell

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BLOOD BRAIN BARRIER; BRAIN TUMOR; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR ESCAPE;

ANIMALS; ANTIGENS, NEOPLASM; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 70349593630     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-009-8114-9     Document Type: Review

References (106)

1. MG Castro R Cowen IK Williamson, et al. 2003 Current and future strategies for the treatment of malignant brain tumors Pharmacol Ther 98 71 108 12667889 1:CAS:528:DC%2BD3sXit12nsbk%3D
2. PR Walker T Calzascia PY Dietrich 2002 All in the head: obstacles for immune rejection of brain tumours Immunology 107 28 38 12225360 1:CAS:528:DC%2BD38XnsFGquro%3D
3. DW Miller 1999 Immunobiology of the blood-brain barrier J Neurovirol 5 570 578 10602398 1:CAS:528:DC%2BD3cXks1OntQ%3D%3D
4. M Weller A Fontana 1995 The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain Brain Res Brain Res Rev 21 128 151 8866671 1:STN:280:DyaK2s%2FitVartA%3D%3D
5. P Medewar 1948 Immunity to homologous grafted skin III. The fate of skin homografts transplanted to the brain, the subcutaneous tissue, and the anterior chamber of the eye Br J Exp Pathol 29 58 69
6. ND Doolittle LE Abrey WA Bleyer, et al. 2005 New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting Clin Cancer Res 11 421 428 15701824
7. SB Read NV Kulprathipanja GG Gomez, et al. 2003 Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification J Interferon Cytokine Res 23 379 393 14511464 1:CAS:528:DC%2BD3sXmtV2ns7k%3D
8. MJ Carson JG Sutcliffe IL Campbell 1999 Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation J Neurosci Res 55 127 134 9890441 1:CAS:528:DyaK1MXjtlWksA%3D%3D
9. F Aloisi F Ria G Penna L Adorini 1998 Microglia are more efficient than astrocytes in antigen processing and in Th1 but not Th2 cell activation J Immunol 160 4671 4680 9590212 1:CAS:528:DyaK1cXjtVansLw%3D
10. J Karman C Ling M Sandor Z Fabry 2004 Initiation of immune responses in brain is promoted by local dendritic cells J Immunol 173 2353 2361 15294948 1:CAS:528:DC%2BD2cXmt1Ols7o%3D
11. KB Quattrocchi CH Miller S Cush, et al. 1999 Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas J Neurooncol 45 141 157 10778730 1:STN:280: DC%2BD3c3jvFSjsw%3D%3D
12. MJ Smyth SL Strobl HA Young JR Ortaldo AC Ochoa 1991 Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta J Immunol 146 3289 3297 1827481 1:CAS:528:DyaK3MXltFantr0%3D
13. TH Inge KM McCoy BM Susskind SK Barrett G Zhao HD Bear 1992 Immunomodulatory effects of transforming growth factor-beta on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes J Immunol 148 3847 3856 1602133 1:CAS:528:DyaK38XksVKmsbw%3D
14. P Jachimczak U Bogdahn J Schneider, et al. 1993 The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma J Neurosurg 78 944 951 8487077 1:CAS:528:DyaK3sXlsFWku78%3D
15. RE Merchant MD Ellison HF Young 1990 Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations J Neurooncol 8 173 188 2193121 1:STN:280:DyaK3c3ptlygtg%3D%3D
16. M Farkkila J Jaaskelainen M Kallio, et al. 1994 Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma Br J Cancer 70 138 141 8018525 1:STN:280:DyaK2c3ovFamug%3D%3D
17. MS Mahaley Jr L Bertsch S Cush GY Gillespie 1988 Systemic gamma-interferon therapy for recurrent gliomas J Neurosurg 69 826 829 3142970
18. A Boiardi A Silvani PA Ruffini, et al. 1994 Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients Cancer Immunol Immunother 39 193 197 7923250 1:STN:280:DyaK2M%2FgslKntw%3D%3D
19. NG Rainov CM Kramm U Banning, et al. 2000 Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme Gene Ther 7 1853 1858 11110418 1:CAS:528: DC%2BD3cXotFaitbc%3D
20. JS Yu G Liu H Ying WH Yong KL Black CJ Wheeler 2004 Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma Cancer Res 64 4973 4979 15256471 1:CAS:528:DC%2BD2cXls1Omt7o%3D
21. RE Merchant NG Baldwin CD Rice HD Bear 1997 Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes Neurol Res 19 145 152 9175143 1:STN:280:DyaK2szhvVWlsg%3D%3D
22. GE Plautz GH Barnett DW Miller, et al. 1998 Systemic T cell adoptive immunotherapy of malignant gliomas J Neurosurg 89 42 51 9647171 1:STN:280:DyaK1czgvFertA%3D%3D
23. D Barba SC Saris C Holder SA Rosenberg EH Oldfield 1989 Intratumoral LAK cell and interleukin-2 therapy of human gliomas J Neurosurg 70 175 182 2643685 1:STN:280:DyaL1M7htVChtw%3D%3D
24. SC Saris NJ Patronas SA Rosenberg, et al. 1989 The effect of intravenous interleukin-2 on brain water content J Neurosurg 71 169 174 2787395 1:STN:280:DyaL1MzhtVOjtA%3D%3D
25. RL Hayes M Koslow EM Hiesiger, et al. 1995 Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma Cancer 76 840 852 8625188 1:CAS:528:DyaK2MXosVejsLY%3D
26. RO Dillman CM Duma PM Schiltz, et al. 2004 Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma J Immunother 27 398 404 15314549
27. CA Kruse L Cepeda B Owens SD Johnson J Stears KO Lillehei 1997 Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 Cancer Immunol Immunother 45 77 87 9390198 1:CAS:528: DyaK2sXotVOju7k%3D
28. F Komatsu M Kajiwara 2000 CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG Oncol Res 12 17 24 11061342 1:CAS:528:DC%2BD3cXnsVClu74%3D
29. J Wischhusen MA Friese M Mittelbronn R Meyermann M Weller 2005 HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo J Neuropathol Exp Neurol 64 523 528 15977644 1:CAS:528:DC%2BD2MXlvVSgtro%3D
30. H Wiendl M Mitsdoerffer V Hofmeister, et al. 2002 A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape J Immunol 168 4772 4780 11971028 1:CAS:528:DC%2BD38Xjt12jurg%3D
31. R Medzhitov CA Janeway Jr 2002 Decoding the patterns of self and nonself by the innate immune system Science 296 298 300 11951031 1:CAS:528: DC%2BD38XjtVWiurg%3D
32. A Wu S Wiesner J Xiao, et al. 2007 Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy J Neurooncol 83 121 131 17077937 1:CAS:528:DC%2BD2sXns1aks7Y%3D
33. MA Friese M Platten SZ Lutz, et al. 2003 MICA/NKG2D-mediated immunogene therapy of experimental gliomas Cancer Res 63 8996 9006 14695218 1:CAS:528:DC%2BD3sXhtVSqtbbK
34. M Girardi DE Oppenheim CR Steele, et al. 2001 Regulation of cutaneous malignancy by gammadelta T cells Science 294 605 609 11567106 1:CAS:528:DC%2BD3MXnslOmtbs%3D
35. MJ Kaminski PD Cruz Jr PR Bergstresser A Takashima 1993 Killing of skin-derived tumor cells by mouse dendritic epidermal T-cells Cancer Res 53 4014 4019 8358730 1:STN:280:DyaK3szmsV2jsg%3D%3D (Pubitemid 23267704)
36. V Groh A Steinle S Bauer T Spies 1998 Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells Science 279 1737 1740 9497295 1:CAS:528:DyaK1cXhvVers78%3D
37. J Wu V Groh T Spies 2002 T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial gamma delta T cells J Immunol 169 1236 1240 12133944 1:CAS:528:DC%2BD38XlslWhsL0%3D
38. CT Morita RA Mariuzza MB Brenner 2000 Antigen recognition by human gamma delta T cells: pattern recognition by the adaptive immune system Springer Semin Immunopathol 22 191 217 11116953 1:CAS:528:DC%2BD3cXnslGjtLc%3D
39. S Bauer V Groh J Wu, et al. 1999 Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA [see comments] Science 285 727 729 10426993 1:CAS:528:DyaK1MXltVehsro%3D
40. V Groh R Rhinehart H Secrist S Bauer KH Grabstein T Spies 1999 Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB Proc Natl Acad Sci USA 96 6879 6884 10359807 1:CAS:528:DyaK1MXks1Wktro%3D
41. R Castriconi A Daga A Dondero, et al. 2009 NK cells recognize and kill human glioblastoma cells with stem cell-like properties J Immunol 182 3530 3539 19265131 1:CAS:528:DC%2BD1MXis12itL0%3D
42. J Vaquero S Coca S Oya R Martinez J Ramiro FG Salazar 1989 Presence and significance of NK cells in glioblastomas J Neurosurg 70 728 731 2540292 1:STN:280:DyaL1M3hsF2quw%3D%3D
43. MA Friese J Wischhusen W Wick, et al. 2004 RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo Cancer Res 64 7596 7603 15492287 1:CAS:528: DC%2BD2cXosFynu7Y%3D
44. G Eisele J Wischhusen M Mittelbronn, et al. 2006 TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells Brain 129 2416 2425 16891318
45. AC Hayday 2000 [gamma][delta] cells: a right time and a right place for a conserved third way of protection Annu Rev Immunol 18 975 1026 10837080 1:CAS:528:DC%2BD3cXjs1Gmt70%3D
46. R Boismenu WL Havran 1997 An innate view of gamma delta T cells Curr Opin Immunol 9 57 63 9039779 1:CAS:528:DyaK2sXhsl2ntLs%3D
47. JL Strominger 1989 The gamma delta T cell receptor and class Ib MHC-related proteins: enigmatic molecules of immune recognition Cell 57 895 898 2525421 1:CAS:528:DyaL1MXksFGgsr0%3D
48. SR Carding PJ Egan 2002 Gammadelta T cells: functional plasticity and heterogeneity Nat Rev Immunol 2 336 345 12033739 1:CAS:528:DC%2BD38Xjsl2rsrY%3D
49. LD McVay SR Carding 1999 Generation of human gammadelta T-cell repertoires Crit Rev Immunol 19 431 460 10647745 1:CAS:528: DC%2BD3cXnvF2ksw%3D%3D
50. G Hacker S Kromer M Falk K Heeg H Wagner K Pfeffer 1992 V delta 1+ subset of human gamma delta T cells responds to ligands expressed by EBV-infected Burkitt lymphoma cells and transformed B lymphocytes J Immunol 149 3984 3989 1334108 1:STN:280:DyaK3s%2FpsVGqtg%3D%3D
51. Z Liu IE Eltoum B Guo BH Beck GA Cloud RD Lopez 2008 Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer J Immunol 180 6044 6053 18424725 1:CAS:528:DC%2BD1cXkvVCjsLg%3D
52. M Ferrarini SM Pupa MR Zocchi C Rugarli S Menard 1994 Distinct pattern of HSP72 and monomeric laminin receptor expression in human lung cancers infiltrated by gamma/delta T lymphocytes Int J Cancer 57 486 490 7514151 1:STN:280:DyaK2c3jslGquw%3D%3D
53. A Choudhary F Davodeau A Moreau MA Peyrat M Bonneville F Jotereau 1995 Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma J Immunol 154 3932 3940 7706731 1:CAS:528:DyaK2MXkvFOrtb0%3D
54. X Zhao YQ Wei Y Kariya K Teshigawara A Uchida 1995 Accumulation of gamma/delta T cells in human dysgerminoma and seminoma: roles in autologous tumor killing and granuloma formation Immunol Invest 24 607 618 7622197 1:STN:280:DyaK2MzkslOktA%3D%3D
55. M Bagot M Heslan L Dubertret JC Roujeau R Tourine JP Levy 1985 Antigen-presenting properties of human epidermal cells compared with peripheral blood mononuclear cells Br J Dermatol 113 suppl 28 55 2410006
56. B Arden SP Clark D Kabelitz TW Mak 1995 Human T-cell receptor variable gene segment families Immunogenetics 42 455 500 8550092 1:CAS:528: DyaK28Xht1Clsb8%3D (Pubitemid 26025063)
57. CT Morita EM Beckman JF Bukowski, et al. 1995 Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells Immunity 3 495 507 7584140 1:CAS:528:DyaK2MXovFymsLk%3D
58. JF Bukowski CT Morita MB Brenner 1999 Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity Immunity 11 57 65 10435579 1:CAS:528:DyaK1MXltFCgtrk%3D
59. V Kunzmann E Bauer J Feurle F Weissinger HP Tony M Wilhelm 2000 Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma Blood 96 384 392 10887096 1:CAS:528:DC%2BD3cXltVGht7c%3D
60. F Miyagawa Y Tanaka S Yamashita 2001 et al. Essential contribution of germline-encoded lysine residues in Jgamma1.2 segment to the recognition of nonpeptide antigens by human gammadelta T cells J Immunol 167 6773 6779 11739492 1:CAS:528:DC%2BD3MXptFGit7k%3D
61. P Fisch M Malkovsky S Kovats, et al. 1990 Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells Science 250 1269 1273 1978758 1:CAS:528:DyaK3MXktVKjtA%3D%3D
62. JF Bukowski CT Morita Y Tanaka BR Bloom MB Brenner H Band 1995 V gamma 2 V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer J Immunol 154 998 1006 7529807 1:CAS:528:DyaK2MXjt1KktLo%3D
63. T Yamaguchi Y Fujimiya Y Suzuki R Katakura T Ebina 1997 A simple method for the propagation and purification of gamma delta T cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2 J Immunol Methods 205 19 28 9236911 1:CAS:528:DyaK2sXkslers7s%3D
64. T Yamaguchi Y Suzuki R Katakura T Ebina J Yokoyama Y Fujimiya 1998 Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood gammadeltaT cells isolated from glioblastoma patients Cancer Immunol Immunother 47 97 103 9769118 1:CAS:528: DyaK1cXmvFWku7s%3D
65. KE Schilbach A Geiselhart JT Wessels D Niethammer R Handgretinger 2000 Human gammadelta T lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells J Immunother 23 536 548 11001547 1:CAS:528: DC%2BD3cXntFCnu7g%3D
66. M Ferrarini E Ferrero L Dagna A Poggi MR Zocchi 2002 Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer Trends Immunol 23 14 18 11801449 1:CAS:528:DC%2BD38Xls1eqtg%3D%3D
67. G Leca N Vita H Maiza M Fasseu A Bensussan 1994 A monoclonal antibody to the Hodgkin's disease-associated antigen CD30 induces activation and long-term growth of human autoreactive gamma delta T cell clone Cell Immunol 156 230 239 8200037 1:CAS:528:DyaK2cXkvVSktLs%3D
68. M Wilhelm V Kunzmann S Eckstein, et al. 2003 Gammadelta T cells for immune therapy of patients with lymphoid malignancies Blood 102 200 206 12623838 1:CAS:528:DC%2BD3sXltFemurk%3D
69. M Bonneville E Scotet 2006 Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors Curr Opin Immunol 18 539 546 16870417 1:CAS:528:DC%2BD28XpsVKqu7k%3D
70. HJ Gober M Kistowska L Angman P Jeno L Mori G De Libero 2003 Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells J Exp Med 197 163 168 12538656 1:CAS:528:DC%2BD3sXmt1Sjtg%3D%3D
71. Y Tanaka CT Morita E Nieves MB Brenner BR Bloom 1995 Natural and synthetic non-peptide antigens recognized by human gamma delta T cells Nature 375 155 158 7753173 1:CAS:528:DyaK2MXls1Wisrk%3D
72. Y Tanaka S Sano E Nieves, et al. 1994 Nonpeptide ligands for human gamma delta T cells Proc Natl Acad Sci USA 91 8175 8179 8058775 1:CAS:528: DyaK2cXlsFGitrY%3D
73. A Poggi R Carosio D Fenoglio, et al. 2004 Migration of V delta 1 and V delta 2 T cells in response to CXCR3 and CXCR4 ligands in healthy donors and HIV-1-infected patients: competition by HIV-1 Tat Blood 103 2205 2213 14630801 1:CAS:528:DC%2BD2cXitlequ7s%3D
74. FM Spada EP Grant PJ Peters, et al. 2000 Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity J Exp Med 191 937 948 10727456 1:CAS:528:DC%2BD3cXitVehsr8%3D
75. DS Leslie MS Vincent FM Spada, et al. 2002 CD1-mediated gamma/delta T cell maturation of dendritic cells J Exp Med 196 1575 1584 12486100 1:CAS:528:DC%2BD38XpslWlurc%3D
76. J Ismaili V Olislagers R Poupot JJ Fournie M Goldman 2002 Human gamma delta T cells induce dendritic cell maturation Clin Immunol 103 296 302 12173304 1:CAS:528:DC%2BD38Xls1Oisr4%3D
77. H Dolstra H Fredrix A van der Meer T de Witte C Figdor E van de Wiel-van Kemenade 2001 TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells Bone Marrow Transplant 27 1087 1093 11438826 1:STN:280: DC%2BD3MznvFOhsA%3D%3D
78. M Duval P Yotnda A Bensussan, et al. 1995 Potential antileukemic effect of gamma delta T cells in acute lymphoblastic leukemia Leukemia 9 863 868 7769850 1:STN:280:DyaK2M3oslKmsQ%3D%3D
79. LS Lamb Jr P Musk Z Ye, et al. 2001 Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response Bone Marrow Transplant 27 601 606 11319589
80. LS Lamb PF Meeh SJ Muga, et al. 2003 Gamma delta T cells from acute leukemia patients show restricted CDR3 rearrangements suggestive of a directed immune response Blood 11 384a
81. ME Scheurer ML Bondy KD Aldape T Albrecht R El-Zein 2008 Detection of human cytomegalovirus in different histological types of gliomas Acta Neuropathol 116 79 86 18351367 1:CAS:528:DC%2BD1cXosVOjtLk%3D
82. SK Lau YY Chen WG Chen, et al. 2005 Lack of association of cytomegalovirus with human brain tumors Mod Pathol 18 838 843 15578071 1:CAS:528:DC%2BD2MXktlWitLw%3D
83. CS Cobbs L Soroceanu S Denham, et al. 2007 Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness J Neurooncol 85 271 280 17589804 1:CAS:528:DC%2BD2sXhsVygt77K
84. DA Mitchell W Xie R Schmittling, et al. 2008 Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma Neuro Oncol 10 10 18 17951512
85. J Odeberg N Wolmer S Falci, et al. 2007 Late human cytomegalovirus (HCMV) proteins inhibit differentiation of human neural precursor cells into astrocytes J Neurosci Res 85 583 593 17154414 1:CAS:528:DC%2BD2sXjtFOksr8%3D
86. J Dechanet P Merville F Berge, et al. 1999 Major expansion of gammadelta T lymphocytes following cytomegalovirus infection in kidney allograft recipients J Infect Dis 179 1 8 9841815 1:STN:280:DyaK1M%2FlvFyntg%3D%3D
87. J Dechanet P Merville A Lim, et al. 1999 Implication of gammadelta T cells in the human immune response to cytomegalovirus J Clin Invest 103 1437 1449 10330426 1:CAS:528:DyaK1MXjt1Wgs78%3D
88. V Pitard D Roumanes X Lafarge, et al. 2008 Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection Blood 112 1317 1324 18539896 1:CAS:528:DC%2BD1cXpvVOktL8%3D
89. F Halary V Pitard D Dlubek, et al. 2005 Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells J Exp Med 201 1567 1578 15897274 1:CAS:528:DC%2BD2MXktlygu7k%3D
90. C Devaud E Bilhere S Loizon, et al. 2009 Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model Cancer Res 69 3971 3978 19383918 1:CAS:528:DC%2BD1MXltFOksbg%3D
91. Y Fujimiya Y Suzuki R Katakura, et al. 1997 In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients Clin Cancer Res 3 633 643 9815731 1:CAS:528:DyaK2sXislGitbs%3D
92. RD Lopez S Xu B Guo RS Negrin EK Waller 2000 CD2-mediated IL-12-dependent signals render human gamma-delta T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies Blood 96 3827 3837 11090067 1:CAS:528:DC%2BD3cXosVGntbs%3D
93. K Sato S Kimura H Segawa, et al. 2005 Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy Int J Cancer 116 94 99 15756684 1:CAS:528:DC%2BD2MXls1Kjt7w%3D
94. N Watanabe M Narita A Yokoyama, et al. 2006 Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate Cytotherapy 8 118 129 16698685 1:CAS:528:DC%2BD28XktVymsrk%3D
95. V Kunzmann E Bauer M Wilhelm 1999 Gamma/delta T-cell stimulation by pamidronate [letter] N Engl J Med 340 737 738 10068336 1:STN:280: DyaK1M7ltVSrsQ%3D%3D
96. S Salot C Laplace S Saiagh, et al. 2007 Large scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product J Immunol Methods 326 63 75 17716681 1:CAS:528:DC%2BD2sXhtVWmtr3N
97. J Bennouna E Bompas EM Neidhardt, et al. 2008 Phase-I study of Innacell gammadeltatrade mark, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma Cancer Immunol Immunother 57 1599 1609 18301889 1:CAS:528:DC%2BD1cXhtVejsbnK
98. D Kabelitz D Wesch W He 2007 Perspectives of gammadelta T cells in tumor immunology Cancer Res 67 5 8 17210676 1:CAS:528:DC%2BD2sXisFWhsg%3D%3D
99. B Guo K Hollmig RD Lopez 2002 Down-regulation of IL-2 receptor a (CD25) characterizes human gd-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12 Cancer Immunol Immunotherapy 50 625 637 1:CAS:528:DC%2BD38XhsVens7g%3D
100. B Guo K Hollmig RD Lopez 2001 In vitro activity of apoptosis-resistant human gd-T cells against solid malignances J Clin Oncol 20 267 (abstract)
101. NL Bryant C Suarez-Cuervo G Gillespie, et al. 2009 Characterization and immunotherapeutic potential of γδ T Cells in patients with glioblastoma Neuro-oncology 11 357 367 19211933 1:CAS:528:DC%2BD1MXhtV2qurzN
102. JH Russell 1995 Activation-induced death of mature T cells in the regulation of immune responses Curr Opin Immunol 7 382 388 7546404 1:CAS:528:DyaK2MXntFaltL0%3D
103. O Janssen S Wesselborg B Heckl-Ostreicher, et al. 1991 T cell receptor/CD3-signaling induces death by apoptosis in human T cell receptor gamma delta+ T cells J Immunol 146 35 39 1824593 1:CAS:528:DyaK3MXpvFGgtA%3D%3D
104. M Ferrarini S Heltai E Toninelli MG Sabbadini C Pellicciari AA Manfredi 1995 Daudi lymphoma killing triggers the programmed death of cytotoxic V gamma 9/V delta 2 T lymphocytes J Immunol 154 3704 3712 7706713 1:CAS:528: DyaK2MXkvFOrtrc%3D
105. K Argentati F Re S Serresi, et al. 2003 Reduced number and impaired function of circulating gamma delta T cells in patients with cutaneous primary melanoma J Invest Dermatol 120 829 834 12713589 1:CAS:528:DC%2BD3sXjslGgu70%3D
106. PF Meeh M King RL O'Brien, et al. 2006 Characterization of the gammadelta T cell response to acute leukemia Cancer Immunol Immunother 55 1072 1080 16328383